• Explore /
  • Poster
  • / A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).

A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).

Abstract Video & Slides Poster

Authors

null

Drew W. Rasco

START, San Antonio, TX

Drew W. Rasco , Johanna C. Bendell , Andrea Wang-Gillam , Wungki Park , Eileen Mary O'Reilly , Lei Zhou , Anna Galkin , Laura L Carter , David Nickle , Jack Li , Beatrice Ferguson , Marya F. Chaney , Jakob Dupont , Wells A. Messersmith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immunobiology

Clinical Trial Registration Number

NCT04060342

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3085)

DOI

10.1200/JCO.2020.38.15_suppl.3085

Abstract #

3085

Poster Bd #

149

Abstract Disclosures

Similar Posters

First Author: Valeria Smiroldo

First Author: Inhwang Hwang

First Author: Zev A. Wainberg

First Author: Michael J. Overman